Stephen J Nicholls1, Rishi Puri2, Kathy Wolski2, Christie M Ballantyne3, Philip J Barter4, H Bryan Brewer5, John J P Kastelein6, Bo Hu2, Kiyoko Uno2, Yu Kataoka7, Jean-Paul R Herrman8, Bela Merkely9, Marilyn Borgman2, Steven E Nissen2. 1. South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia. stephen.nicholls@sahmri.com. 2. Department of Cardiovascular Medicine and Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, OH, USA. 3. Section of Cardiovascular Research, Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, TX, USA. 4. University of New South Wales, Sydney, NSW, Australia. 5. Medstar Research Institute, Hyattsville, MD, USA. 6. Department of Vascular Medicine, Academic Medical Center, University of Medicine, Amsterdam, The Netherlands. 7. South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA, 5001, Australia. 8. Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. 9. Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
Abstract
BACKGROUND:Bromodomain and extra-terminal (BET) proteins regulate transcription of lipoprotein and inflammatory factors implicated in atherosclerosis. The impact of BET inhibition on atherosclerosis progression is unknown. METHODS: ASSURE was a double-blind, randomized, multicenter trial in which 323 patients with angiographic coronary disease and low high-density lipoprotein cholesterol (HDL-C) levels were randomized in a 3:1 fashion to treatment with the BET protein inhibitor RVX-208 200 mg or placebo for 26 weeks. Plaque progression was measured with serial intravascular ultrasound imaging. Lipid levels, safety, and tolerability were also assessed. RESULTS: During treatment, apolipoprotein (apo)A-I increased by 10.6% with placebo (P < 0.001 compared with baseline) and 12.8% with RVX-208 (P < 0.001 compared with baseline), between groups P = 0.18. HDL-C increased by 9.1% with placebo (P < 0.001 compared with baseline) and 11.1% with RVX-208 (P < 0.001 compared with baseline), between groups P = 0.24. Low-density lipoprotein cholesterol (LDL-C) decreased by 17.9% with placebo (P < 0.001 compared with baseline) and 15.8% with RVX-208 (P < 0.001 compared with baseline), between groups P = 0.55. The primary endpoint, the change in percent atheroma volume, decreased 0.30% in placebo-treated patients (P = 0.23 compared with baseline) and 0.40% in the RVX-208 group (P = 0.08 compared with baseline), between groups P = 0.81. Total atheroma volume decreased 3.8 mm(3) in the placebo group (P = 0.01 compared with baseline) and 4.2 mm(3) in the RVX-208 group (P < 0.001 compared with baseline), P = 0.86 between groups. A greater incidence of elevated liver enzymes was observed in RVX-208-treated patients (7.1 vs. 0%, P = 0.009). CONCLUSION: Administration of the BET protein inhibitor RVX-208 showed no greater increase in apoA-I or HDL-C or incremental regression of atherosclerosis than administration of placebo. TRIAL REGISTRATION: ClinicalTrials.gov identifier-NCT01067820.
RCT Entities:
BACKGROUND: Bromodomain and extra-terminal (BET) proteins regulate transcription of lipoprotein and inflammatory factors implicated in atherosclerosis. The impact of BET inhibition on atherosclerosis progression is unknown. METHODS: ASSURE was a double-blind, randomized, multicenter trial in which 323 patients with angiographic coronary disease and low high-density lipoprotein cholesterol (HDL-C) levels were randomized in a 3:1 fashion to treatment with the BET protein inhibitor RVX-208 200 mg or placebo for 26 weeks. Plaque progression was measured with serial intravascular ultrasound imaging. Lipid levels, safety, and tolerability were also assessed. RESULTS: During treatment, apolipoprotein (apo)A-I increased by 10.6% with placebo (P < 0.001 compared with baseline) and 12.8% with RVX-208 (P < 0.001 compared with baseline), between groups P = 0.18. HDL-C increased by 9.1% with placebo (P < 0.001 compared with baseline) and 11.1% with RVX-208 (P < 0.001 compared with baseline), between groups P = 0.24. Low-density lipoprotein cholesterol (LDL-C) decreased by 17.9% with placebo (P < 0.001 compared with baseline) and 15.8% with RVX-208 (P < 0.001 compared with baseline), between groups P = 0.55. The primary endpoint, the change in percent atheroma volume, decreased 0.30% in placebo-treated patients (P = 0.23 compared with baseline) and 0.40% in the RVX-208 group (P = 0.08 compared with baseline), between groups P = 0.81. Total atheroma volume decreased 3.8 mm(3) in the placebo group (P = 0.01 compared with baseline) and 4.2 mm(3) in the RVX-208 group (P < 0.001 compared with baseline), P = 0.86 between groups. A greater incidence of elevated liver enzymes was observed in RVX-208-treated patients (7.1 vs. 0%, P = 0.009). CONCLUSION: Administration of the BET protein inhibitor RVX-208 showed no greater increase in apoA-I or HDL-C or incremental regression of atherosclerosis than administration of placebo. TRIAL REGISTRATION: ClinicalTrials.gov identifier-NCT01067820.
Authors: Michael Daskalakis; David Brocks; Yi-Hua Sheng; Md Saiful Islam; Alzbeta Ressnerova; Yassen Assenov; Till Milde; Ina Oehme; Olaf Witt; Ashish Goyal; Alexander Kühn; Mark Hartmann; Dieter Weichenhan; Manfred Jung; Christoph Plass Journal: Cell Cycle Date: 2018-04-30 Impact factor: 4.534
Authors: Jordan Andrews; Alex Janssan; Tracy Nguyen; Anthony D Pisaniello; Daniel J Scherer; John J P Kastelein; Bela Merkely; Steven E Nissen; Kausik Ray; Gregory G Schwartz; Stephen G Worthley; Connie Keyserling; Jean-Louis Dasseux; Julie Butters; Jacinta Girardi; Rosemary Miller; Stephen J Nicholls Journal: Cardiovasc Diagn Ther Date: 2017-02
Authors: Yujun Zhao; Bing Zhou; Longchuan Bai; Liu Liu; Chao-Yie Yang; Jennifer L Meagher; Jeanne A Stuckey; Donna McEachern; Sally Przybranowski; Mi Wang; Xu Ran; Angelo Aguilar; Yang Hu; Jeff W Kampf; Xiaoqin Li; Ting Zhao; Siwei Li; Bo Wen; Duxin Sun; Shaomeng Wang Journal: J Med Chem Date: 2018-07-17 Impact factor: 7.446
Authors: Kausik K Ray; Stephen J Nicholls; Kevin A Buhr; Henry N Ginsberg; Jan O Johansson; Kamyar Kalantar-Zadeh; Ewelina Kulikowski; Peter P Toth; Norman Wong; Michael Sweeney; Gregory G Schwartz Journal: JAMA Date: 2020-04-28 Impact factor: 56.272